TY - JOUR
T1 - Indolent and mantle cell NHL
T2 - The future is BRIGHT
AU - Fowler, Nathan
PY - 2014/5/8
Y1 - 2014/5/8
N2 - In this issue of Blood, Flinn et al report a phase 3 study demonstrating similar complete response rates with bendamustine and rituximab compared with rituximab plus cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) in untreated indolent and mantle cell lymphomas.
AB - In this issue of Blood, Flinn et al report a phase 3 study demonstrating similar complete response rates with bendamustine and rituximab compared with rituximab plus cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) in untreated indolent and mantle cell lymphomas.
UR - http://www.scopus.com/inward/record.url?scp=84900404201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900404201&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-03-562124
DO - 10.1182/blood-2014-03-562124
M3 - Review article
C2 - 24810622
AN - SCOPUS:84900404201
SN - 0006-4971
VL - 123
SP - 2905
EP - 2906
JO - Blood
JF - Blood
IS - 19
ER -